NEPH vs DHR

For growth investors, Nephros, Inc.

(NEPH) is the stronger pick with 32. 7% revenue growth year-over-year, versus 2. 9% for Danaher Corporation (DHR). Nephros, Inc. (NEPH) offers the better valuation at 29. 4x trailing P/E, making it the more compelling value choice. Analysts rate Danaher Corporation (DHR) a "Buy" — based on 42 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Nephros, Inc.

(NEPH) is the cheapest at 29. 4x versus Danaher Corporation at 34. 9x.

Over the past 5 years, Danaher Corporation (DHR) delivered a total return of -21.

1%, compared to -56. 3% for Nephros, Inc. (NEPH). Over 10 years, the gap is even starker: DHR returned +219. 3% versus NEPH's +2. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Nephros, Inc.

(NEPH) is the lower-risk stock at 0. 59β versus Danaher Corporation's 0. 94β — meaning DHR is approximately 58% more volatile than NEPH relative to the S&P 500. On balance sheet safety, Nephros, Inc. (NEPH) carries a lower debt/equity ratio of 10% versus 35% for Danaher Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Nephros, Inc.

(NEPH) is pulling ahead at 32. 7% versus 2. 9% for Danaher Corporation (DHR). Over a 3-year CAGR, NEPH leads at 23. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Danaher Corporation (DHR) is the more profitable company, earning 14.

7% net margin versus 6. 4% for Nephros, Inc. — meaning it keeps 14. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DHR leads at 20. 9% versus 6. 1% for NEPH. At the gross margin level — before operating expenses — NEPH leads at 61. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, DHR (0.

7% yield) pays a dividend. NEPH does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Danaher Corporation (DHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

94), 0. 7% yield, +219. 3% 10Y return). Both have compounded well over 10 years (DHR: +219. 3%, NEPH: +2. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: NEPH is a small-cap high-growth stock; DHR is a mid-cap quality compounder stock. DHR pays a dividend while NEPH does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.